Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 352 followers
Latest posts
Last updated 2 days ago
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
2 days ago
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than...
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
4 days ago
Patients on fenebrutinib had low relapse rates with data showing no active...
Invitation to Roche’s Virtual Hematology Investor Event
7 days ago
We are pleased to invite investors and analysts to participate in our...
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
10 days ago
Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in...
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
11 days ago
The strategic collaboration with Broad Clinical Labs will explore and develop applications...
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
11 days ago
Updated data from the pivotal phase III STARGLO study continue to demonstrate...
FDA approves Roche’s Susvimo for diabetic retinopathy
11 days ago
Susvimo can help people with diabetic retinopathy (DR) maintain their vision and...
Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
13 days ago
Columvi is the first bispecific antibody to show a statistically significant and...
Reminder: Invitation to Roche’s Diagnostics Day 2025
13 days ago
The Roche Investor Relations team would like to invite you to the...
Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer
21 days ago
Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit...
Reminder: Invitation to Roche’s Diagnostics Day 2025
25 days ago
The Roche Investor Relations team would like to invite you to the...
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity
28 days ago
Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets)...